MovDisordV3, PascalFrancis, Curation, bibRecord, 001150

Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset

Identifieur interne : 001150 ( PascalFrancis/Curation ); précédent : 001149; suivant : 001151

Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset

Auteurs : Georgios M. Hadjigeorgiou [Grèce] ; Georgia Xiromerisiou [Grèce, États-Unis] ; Vanessa Gourbali [Grèce] ; Kostantinos Aggelakis [Grèce] ; Nikolaos Scarmeas [Grèce, États-Unis] ; Alexandros Papadimitriou [Grèce] ; Andrew Singleton [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0244418

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Polymorphisme, Age apparition.

English descriptors

KwdEn :
- Age of onset, Nervous system diseases, Parkinson disease, Polymorphism.

Abstract

The α-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21: 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset`
A11	`01`	`1`		`@1 HADJIGEORGIOU (Georgios M.)`
A11	`02`	`1`		`@1 XIROMERISIOU (Georgia)`
A11	`03`	`1`		`@1 GOURBALI (Vanessa)`
A11	`04`	`1`		`@1 AGGELAKIS (Kostantinos)`
A11	`05`	`1`		`@1 SCARMEAS (Nikolaos)`
A11	`06`	`1`		`@1 PAPADIMITRIOU (Alexandros)`
A11	`07`	`1`		`@1 SINGLETON (Andrew)`
A14	`01`			`@1 Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly @2 Larissa @3 GRC @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health @2 Bethesda, Maryland @3 USA @Z 2 aut. @Z 7 aut.`
A14	`03`			`@1 Cognitive Neuroscience Division, Taub Institute, Department of Neurology, Columbia University Medical Center @2 New York, New York @3 USA @Z 5 aut.`
A20				`@1 534-539`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000156737350160`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 06-0244418`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The α-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21: 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Polymorphisme @5 09`
C03	`03`	`X`	`ENG`	`@0 Polymorphism @5 09`
C03	`03`	`X`	`SPA`	`@0 Polimorfismo @5 09`
C03	`04`	`X`	`FRE`	`@0 Age apparition @5 10`
C03	`04`	`X`	`ENG`	`@0 Age of onset @5 10`
C03	`04`	`X`	`SPA`	`@0 Edad aparición @5 10`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 156`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B71

Links to Exploration step

Pascal:06-0244418

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset</title>
<author><name sortKey="Hadjigeorgiou, Georgios M" sort="Hadjigeorgiou, Georgios M" uniqKey="Hadjigeorgiou G" first="Georgios M." last="Hadjigeorgiou">Georgios M. Hadjigeorgiou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Xiromerisiou, Georgia" sort="Xiromerisiou, Georgia" uniqKey="Xiromerisiou G" first="Georgia" last="Xiromerisiou">Georgia Xiromerisiou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gourbali, Vanessa" sort="Gourbali, Vanessa" uniqKey="Gourbali V" first="Vanessa" last="Gourbali">Vanessa Gourbali</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Aggelakis, Kostantinos" sort="Aggelakis, Kostantinos" uniqKey="Aggelakis K" first="Kostantinos" last="Aggelakis">Kostantinos Aggelakis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Scarmeas, Nikolaos" sort="Scarmeas, Nikolaos" uniqKey="Scarmeas N" first="Nikolaos" last="Scarmeas">Nikolaos Scarmeas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cognitive Neuroscience Division, Taub Institute, Department of Neurology, Columbia University Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Papadimitriou, Alexandros" sort="Papadimitriou, Alexandros" uniqKey="Papadimitriou A" first="Alexandros" last="Papadimitriou">Alexandros Papadimitriou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Singleton, Andrew" sort="Singleton, Andrew" uniqKey="Singleton A" first="Andrew" last="Singleton">Andrew Singleton</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0244418</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0244418 INIST</idno>
<idno type="RBID">Pascal:06-0244418</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B71</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001150</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset</title>
<author><name sortKey="Hadjigeorgiou, Georgios M" sort="Hadjigeorgiou, Georgios M" uniqKey="Hadjigeorgiou G" first="Georgios M." last="Hadjigeorgiou">Georgios M. Hadjigeorgiou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Xiromerisiou, Georgia" sort="Xiromerisiou, Georgia" uniqKey="Xiromerisiou G" first="Georgia" last="Xiromerisiou">Georgia Xiromerisiou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gourbali, Vanessa" sort="Gourbali, Vanessa" uniqKey="Gourbali V" first="Vanessa" last="Gourbali">Vanessa Gourbali</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Aggelakis, Kostantinos" sort="Aggelakis, Kostantinos" uniqKey="Aggelakis K" first="Kostantinos" last="Aggelakis">Kostantinos Aggelakis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Scarmeas, Nikolaos" sort="Scarmeas, Nikolaos" uniqKey="Scarmeas N" first="Nikolaos" last="Scarmeas">Nikolaos Scarmeas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cognitive Neuroscience Division, Taub Institute, Department of Neurology, Columbia University Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Papadimitriou, Alexandros" sort="Papadimitriou, Alexandros" uniqKey="Papadimitriou A" first="Alexandros" last="Papadimitriou">Alexandros Papadimitriou</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Singleton, Andrew" sort="Singleton, Andrew" uniqKey="Singleton A" first="Andrew" last="Singleton">Andrew Singleton</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age of onset</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Polymorphism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Polymorphisme</term>
<term>Age apparition</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The α-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21: 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HADJIGEORGIOU (Georgios M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>XIROMERISIOU (Georgia)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GOURBALI (Vanessa)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AGGELAKIS (Kostantinos)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SCARMEAS (Nikolaos)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PAPADIMITRIOU (Alexandros)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SINGLETON (Andrew)</s1>
</fA11>
<fA14 i1="01"><s1>Neurogenetics Unit, Department of Neurology, Medical School, University of Thessaly</s1>
<s2>Larissa</s2>
<s3>GRC</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Molecular Genetics Section, Laboratory of Neurogenetics, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Cognitive Neuroscience Division, Taub Institute, Department of Neurology, Columbia University Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>534-539</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000156737350160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0244418</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The α-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21: 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Age apparition</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Age of onset</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Edad aparición</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>156</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001150 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001150 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0244418
   |texte=   Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset

Association of α-synuclein Rep1 polymorphism and parkinson's disease : Influence of Rep1 on age at onset

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri